3,4-Dimethoxyphenylethylamine



Compound IDCDAMM01849
Common name3,4-Dimethoxyphenylethylamine
IUPAC name2-(3,4-dimethoxyphenyl)ethanamine
Molecular formulaC10H15NO2

Experimental data

Retention time0.68
Adduct[M+H]+
Actual mz182.12
Theoretical mz182.117
Error12.76
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score8.1402

Identifiers and class information

Inchi keyANOUKFYBOAKOIR-UHFFFAOYSA-N
SmilesO(C1=CC=C(C=C1OC)CCN)C
SuperclassBenzenoids
ClassBenzene and substituted derivatives

Plant source

  • Curcuma longa L.

    • Pharmacokinetic properties

    Number of descriptor values(#stars)0
    Number of non-conjugated amine groups (#amine)1
    Number of amidine and guanidine groups (#amidine)0
    Number of carboxylic acid groups (#acid)0
    Number of non-conjugated amide groups (#amide)0
    Number of rotatable bonds (#rotor)5
    Number of reactive functional groups (#rtvFG)0
    Predicted central nervous system activity (CNS)1
    Molecular weight (mol_MW)181.234
    Computed dipole moment(dipole)1.978
    Total solvent accessible surface area (SASA)422.505
    Hydrophobic component of SASA (FOSA)270.218
    Hydrophilic component of SASA (FISA)64.615
    Pie component of the SASA (PISA)87.672
    Weakly polar component of the SASA (WPSA)0
    Total solvent accesible volume (volume)686.645
    Number of hydrogen bond donors (donorHB)2
    Number of hydrogen bond acceptors (accptHB)2.5
    Free energy of solvation of dipole (dip^2/V)0.0056969
    Index of cohesive interaction in solids (ACxDN^.5/SA)0.008368
    Globularity descriptor (glob)0.890886
    Predicted polarizability in cubic angstroms (QPpolrz)18.952
    Predicted hexadecane/gas partition coefficient (QPlogPC16)6.133
    Predicted octanol/gas partition coefficient (QPlogPoct)9.639
    Predicted water/gas partition coefficient (QPlogPw)6.06
    Predicted octanol/water partition coefficient (QPlogPo/w)1.808
    Predicted aqueous solubility (QPlogS)-0.886
    Conformation-independent predicted aqueous solubility (CIQPlogS)-1.14
    Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.442
    Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)602.641
    Predicted brain/blood partition coefficient (QPlogBB)0.118
    Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)316.592
    Predicted skin permeability, log Kp (QPlogKp)-3.984
    PM3 calculated ionization potential (IP(ev))8.729
    PM3 calculated electron affinity (EA(eV))-0.201
    Number of likely metabolic reactions (#metab)5
    Prediction of binding to human serum albumin (QPlogKhsa)-0.276
    Predicted qualitative human oral absorption (HumanOralAbsorption)3
    Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)87.291
    Solvent-accessible surface area of fluorine atoms (SAFluorine)0
    Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
    Van der Waals surface area (PSA)43.45
    Number of nitrogen and oxygen atoms (#NandO)3
    Number of violations of Lipinski’s rule of five (RuleOfFive)0
    Number of violations of Jorgensen’s rule of three (RuleOfThree)0

    Compound-target network

    Cytoscape Graph

    Protein targets associated with phytocompound

    Uniprot ID Gene name Target name TTD_ID Prediction source
    P22303ACHEAcetylcholinesteraseT30082SEA
    Q16853AOC3Amine oxidase, copper containingT69619SwissTargetPrediction and SEA
    Q99720SIGMAR1Sigma opioid receptorT46360SEA
    P02766TTRTransthyretinT86462SEA
    P14416DRD2Dopamine D2 receptorT67162SwissTargetPrediction
    Q15125EBPAnti-estrogen binding site (AEBS)T25317SEA
    P43166CA7Carbonic anhydrase VIIT37541SEA
    P23280CA6Carbonic anhydrase VIT06569SEA
    Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
    P28223HTR2ASerotonin 2a (5-HT2a) receptorT32060SwissTargetPrediction and SEA
    P28335HTR2CSerotonin 2c (5-HT2c) receptorT83813SwissTargetPrediction and SEA
    P31645SLC6A4Serotonin transporter (by homology)T27812SwissTargetPrediction
    Q96RJ0TAAR1Trace amine-associated receptor 1 (by homology)T99524SEA
    P41595HTR2BSerotonin 2b (5-HT2b) receptorT31204SwissTargetPrediction and SEA
    Q01959SLC6A3Dopamine transporterT55959SwissTargetPrediction
    P25021HRH2Histamine H2 receptorT30985SEA
    P35462DRD3Dopamine D3 receptorT02551SwissTargetPrediction
    P23975SLC6A2Norepinephrine transporterT21945SwissTargetPrediction
    P08183ABCB1P-glycoprotein 1T25258SEA
    P16050ALOX15Arachidonate 15-lipoxygenaseT16042SEA
    Q08499PDE4DPhosphodiesterase 4DT02001SEA
    Q14432PDE3APhosphodiesterase 3T88975SEA
    P34995PTGER1Prostanoid EP1 receptorT15497SEA
    Q16620NTRK2Neurotrophic tyrosine kinase receptor type 2T84703SEA
    P35346SSTR5Somatostatin receptor 5T64830SEA
    Q9UNQ0ABCG2ATP-binding cassette sub-family G member 2T56556SEA
    P00374DHFRDihydrofolate reductaseT17345SEA
    Q13370PDE3BPhosphodiesterase 3BT21357SEA
    Q13936CACNA1CVoltage-gated L-type calcium channel alpha-1C subunitT51115SEA
    Q16678CYP1B1Cytochrome P450 1B1T92521SEA
    Q92952KCNN1Small conductance calcium-activated potassium channel protein 1T11911SEA
    Q9UGI6KCNN3Small conductance calcium-activated potassium channel protein 3T04388SEA
    P19438TNFRSF1ATumor necrosis factor receptor R1T86552SEA
    Q16236NFE2L2Nuclear factor erythroid 2-related factor 2T88505SEA
    Q02790FKBP4FK506 binding protein 4T87020SEA
    Q9Y3Q4HCN4Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4T30286SEA
    Q9H2S1KCNN2Small conductance calcium-activated potassium channel protein 2T86271SEA
    Q9H4B7TUBB1Tubulin beta-1 chainT84397SEA
    Q9Y4K0LOXL2Lysyl oxidase homolog 2T25637SEA
    Q9NZQ8TRPM5Long transient receptor potential channel 5T85545SEA
    P10323ACRAcrosinT24595SEA
    Q96HK3CALMCalmodulinT39610SEA
    O60755GALR3Galanin receptorT98494SEA
    O14804TAAR5Trace amine receptor 5T60362SEA

    Target associated diseases

    TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
    T30082DI0025Alzheimer disease[ICD-11: 8A20]P22303ACHE
    T30082DI0166Glaucoma[ICD-11: 9C61]P22303ACHE
    T30082DI0282Myasthenia gravis[ICD-11: 8C6Y]P22303ACHE
    T30082DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P22303ACHE
    T30082DI0332Pediculosis[ICD-11: 1G00]P22303ACHE
    T30082DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P22303ACHE
    T69619DI0190Hypertension[ICD-11: BA00-BA04]Q16853AOC3
    T46360DI0105Cough[ICD-11: MD12]Q99720SIGMAR1
    T86462DI0026Amyloidosis[ICD-11: 5D00]P02766TTR
    T67162DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P14416DRD2
    T67162DI0025Alzheimer disease[ICD-11: 8A20]P14416DRD2
    T67162DI0037Asthma[ICD-11: CA23]P14416DRD2
    T67162DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P14416DRD2
    T67162DI0051Bipolar disorder[ICD-11: 6A60]P14416DRD2
    T67162DI0063Breathing abnormality[ICD-11: MD11]P14416DRD2
    T67162DI0070Cardiovascular disease[ICD-11: BA00-BE2Z]P14416DRD2
    T67162DI0073Cerebral ischaemia[ICD-11: 8B1Z]P14416DRD2
    T67162DI0117Depression[ICD-11: 6A70-6A7Z]P14416DRD2
    T67162DI0124Digestive system disease[ICD-11: DE2Z]P14416DRD2
    T67162DI0137Essential hypertension[ICD-11: BA00]P14416DRD2
    T67162DI0142Faecal incontinence[ICD-11: ME07]P14416DRD2
    T67162DI0156Gangrene[ICD-11: MC85]P14416DRD2
    T67162DI0166Glaucoma[ICD-11: 9C61]P14416DRD2
    T67162DI0175Heart failure[ICD-11: BD10-BD1Z]P14416DRD2
    T67162DI0185Hyperaemia[ICD-11: 9A61-9B7Y]P14416DRD2
    T67162DI0190Hypertension[ICD-11: BA00-BA04]P14416DRD2
    T67162DI0196Hypotension[ICD-11: BA20-BA21]P14416DRD2
    T67162DI0205Inborn porphyrin/heme metabolism error[ICD-11: 5C58]P14416DRD2
    T67162DI0214Insomnia[ICD-11: 7A00-7A0Z]P14416DRD2
    T67162DI0222Itching[ICD-11: 1F28-1G07]P14416DRD2
    T67162DI0264Migraine[ICD-11: 8A80]P14416DRD2
    T67162DI0293Nausea/vomiting[ICD-11: MD90]P14416DRD2
    T67162DI0324Pain[ICD-11: MG30-MG3Z]P14416DRD2
    T67162DI0331Parkinsonism[ICD-11: 8A00]P14416DRD2
    T67162DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P14416DRD2
    T67162DI0340Postpartum haemorrhage[ICD-11: JA43]P14416DRD2
    T67162DI0354Psychotic disorder[ICD-11: 6A20-6A25]P14416DRD2
    T67162DI0356Pulmonary hypertension[ICD-11: BB01]P14416DRD2
    T67162DI0370Schizophrenia[ICD-11: 6A20]P14416DRD2
    T67162DI0396Substance abuse[ICD-11: 6C40]P14416DRD2
    T67162DI0408Thyrotoxicosis[ICD-11: 5A02]P14416DRD2
    T67162DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P14416DRD2
    T25317DI0366Rheumatoid arthritis[ICD-11: FA20]Q15125EBP
    T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
    T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
    T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
    T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
    T32060DI0009Acute diabete complication[ICD-11: 5A2Y]P28223HTR2A
    T32060DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P28223HTR2A
    T32060DI0073Cerebral ischaemia[ICD-11: 8B1Z]P28223HTR2A
    T32060DI0270Mood disorder[ICD-11: 6A60-6E23]P28223HTR2A
    T32060DI0331Parkinsonism[ICD-11: 8A00]P28223HTR2A
    T32060DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28223HTR2A
    T32060DI0370Schizophrenia[ICD-11: 6A20]P28223HTR2A
    T83813DI0117Depression[ICD-11: 6A70-6A7Z]P28335HTR2C
    T83813DI0264Migraine[ICD-11: 8A80]P28335HTR2C
    T83813DI0308Obesity[ICD-11: 5B80-5B81]P28335HTR2C
    T83813DI0324Pain[ICD-11: MG30-MG3Z]P28335HTR2C
    T83813DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28335HTR2C
    T27812DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P31645SLC6A4
    T27812DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P31645SLC6A4
    T27812DI0087Chronic pain[ICD-11: MG30]P31645SLC6A4
    T27812DI0096concerning food/fluid intake symptom[ICD-11: MG43]P31645SLC6A4
    T27812DI0101Corneal disease[ICD-11: 9A76-9A78]P31645SLC6A4
    T27812DI0105Cough[ICD-11: MD12]P31645SLC6A4
    T27812DI0117Depression[ICD-11: 6A70-6A7Z]P31645SLC6A4
    T27812DI0264Migraine[ICD-11: 8A80]P31645SLC6A4
    T27812DI0301Nicotine use disorder[ICD-11: 6C4A]P31645SLC6A4
    T27812DI0308Obesity[ICD-11: 5B80-5B81]P31645SLC6A4
    T27812DI0324Pain[ICD-11: MG30-MG3Z]P31645SLC6A4
    T99524DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]Q96RJ0TAAR1
    T99524DI0149Focal/segmental autonomic disorder[ICD-11: 8D8A]Q96RJ0TAAR1
    T99524DI0290Narcolepsy[ICD-11: 7A20]Q96RJ0TAAR1
    T31204DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P41595HTR2B
    T31204DI0117Depression[ICD-11: 6A70-6A7Z]P41595HTR2B
    T31204DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P41595HTR2B
    T31204DI0354Psychotic disorder[ICD-11: 6A20-6A25]P41595HTR2B
    T55959DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]Q01959SLC6A3
    T55959DI0051Bipolar disorder[ICD-11: 6A60]Q01959SLC6A3
    T55959DI0101Corneal disease[ICD-11: 9A76-9A78]Q01959SLC6A3
    T55959DI0290Narcolepsy[ICD-11: 7A20]Q01959SLC6A3
    T55959DI0308Obesity[ICD-11: 5B80-5B81]Q01959SLC6A3
    T55959DI0331Parkinsonism[ICD-11: 8A00]Q01959SLC6A3
    T30985DI0161Gastro-oesophageal reflux disease[ICD-11: DA22]P25021HRH2
    T30985DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P25021HRH2
    T30985DI0333Peptic ulcer[ICD-11: DA61]P25021HRH2
    T02551DI0051Bipolar disorder[ICD-11: 6A60]P35462DRD3
    T02551DI0331Parkinsonism[ICD-11: 8A00]P35462DRD3
    T21945DI0013Acute pain[ICD-11: MG31]P23975SLC6A2
    T21945DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P23975SLC6A2
    T21945DI0087Chronic pain[ICD-11: MG30]P23975SLC6A2
    T21945DI0101Corneal disease[ICD-11: 9A76-9A78]P23975SLC6A2
    T21945DI0117Depression[ICD-11: 6A70-6A7Z]P23975SLC6A2
    T21945DI0166Glaucoma[ICD-11: 9C61]P23975SLC6A2
    T21945DI0264Migraine[ICD-11: 8A80]P23975SLC6A2
    T21945DI0301Nicotine use disorder[ICD-11: 6C4A]P23975SLC6A2
    T21945DI0308Obesity[ICD-11: 5B80-5B81]P23975SLC6A2
    T21945DI0324Pain[ICD-11: MG30-MG3Z]P23975SLC6A2
    T21945DI0395Stomach cancer[ICD-11: 2B72]P23975SLC6A2
    T25258DI0238Lung cancer[ICD-11: 2C25]P08183ABCB1
    T02001DI0411Tonus and reflex abnormality[ICD-11: MB47]Q08499PDE4D
    T88975DI0035Arterial occlusive disease[ICD-11: BD40]Q14432PDE3A
    T88975DI0037Asthma[ICD-11: CA23]Q14432PDE3A
    T88975DI0175Heart failure[ICD-11: BD10-BD1Z]Q14432PDE3A
    T88975DI0404Thrombocytosis[ICD-11: 3B63]Q14432PDE3A
    T15497DI0405Thrombosis[ICD-11: DB61-GB90]P34995PTGER1
    T84703DI0303Non-small-cell lung cancer[ICD-11: 2C25]Q16620NTRK2
    T84703DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16620NTRK2
    T64830DI0108Cushing syndrome[ICD-11: 5A70]P35346SSTR5
    T56556DI0218Irritable bowel syndrome[ICD-11: DD91]Q9UNQ0ABCG2
    T56556DI0366Rheumatoid arthritis[ICD-11: FA20]Q9UNQ0ABCG2
    T17345DI0207Indeterminate colitis[ICD-11: DD72]P00374DHFR
    T17345DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P00374DHFR
    T17345DI0416Tuberculosis[ICD-11: 1B10-1B12]P00374DHFR
    T17345DI0427Urinary tract infection[ICD-11: GC08]P00374DHFR
    T51115DI0025Alzheimer disease[ICD-11: 8A20]Q13936CACNA1C
    T11911DI0285Myelopathy[ICD-11: 8B42]Q92952KCNN1
    T04388DI0285Myelopathy[ICD-11: 8B42]Q9UGI6KCNN3
    T86552DI0060Brain cancer[ICD-11: 2A00]P19438TNFRSF1A
    T86552DI0321Ovarian cancer[ICD-11: 2C73]P19438TNFRSF1A
    T88505DI0038Ataxic disorder[ICD-11: 8A03]Q16236NFE2L2
    T86271DI0285Myelopathy[ICD-11: 8B42]Q9H2S1KCNN2
    T84397DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9H4B7TUBB1
    T25637DI0095Colorectal cancer[ICD-11: 2B91]Q9Y4K0LOXL2
    T39610DI0068Cardiac arrhythmia[ICD-11: BC9Z]Q96HK3CALM
    T39610DI0243Malaria[ICD-11: 1F40-1F45]Q96HK3CALM
    T39610DI0370Schizophrenia[ICD-11: 6A20]Q96HK3CALM
    T98494DI0265Mild neurocognitive disorder[ICD-11: 6D71]O60755GALR3

    Copyright © 2025